In this study, the performance of phase separated and crystallized amorphous solid dispersions (ASDs) was evaluated by non-sink in vitro dissolution testing in fasted-state simulated intestinal fluid (FaSSIF) and in vivo in rats. The amorphous phase-separated or crystallized ASDs were prepared by mixing an ASD of the model drug celecoxib (CCX) in polyvinylpyrrolidone (PVP) with pure amorphous or micronized crystalline CCX at 20, 40, 60 or 100% of the total drug load (25:75 w/w CCX:PVP), respectively. As expected, crystallization of CCX in the ASDs generally had a negative influence on both the area under the curve of the dissolution curve (in vitro AUC) and the plasma concentration-time profile (in vivo AUC) in rats compared to the pure ASD. However, the difference between the in vivo AUC of the pure ASD and the 20% and 40% crystallized ASDs was not statistically significant, which could indicate that a low fraction of crystallization of a drug in an ASD may only have limited impact on in vivo performance and hence bioavailability. In comparison, amorphous phase separation of CCX in the ASDs did not negatively influence the in vitro AUC and in vivo AUC to the same degree as crystallization and the dissolution profiles of all the amorphous phase-separated ASDs were similar to that of the pure ASD. In fact, even though a slight decrease of in vivo AUC with increasing fraction of amorphous phase separation was observed, the 20% and 40% amorphous phase-separated ASDs were bioequivalent with the pure ASD.
Introduction
Oral drug delivery has always been the preferred route of administration of pharmaceuticals, both from the patient's perspective due to convenience and compliance, and from the manufacturer's perspective due to long shelf life and limited cost of production [1, 9, 2] . However, as a result of advanced high-throughput screening methods and the implementation of computational chemistry, the pharmaceutical industry is currently experiencing an increase in the amount of complex drug molecules. These more complex molecules in most cases entail a solubility limitation that challenges the oral delivery of these drugs, and has prompted the development of different so-called enabling formulation strategies to overcome the solubility limitations, including amorphous solid dispersions (ASDs) [14, 2, 13, 4 ]. An ASD is a molecular dispersion of a drug in an amorphous polymer, commonly prepared by melt-based method such as hot-melt extrusion or solvent-based method such as spray drying, and less commonly by freeze-drying or milling [15, 17, 9] . The aim of this enabling formulation approach is first of all to increase the free energy of the drug and thus, its apparent solubility through amorphization and secondly, to stabilize the inherently unstable amorphous form of the drug through intermolecular interactions with the polymer [14, 16] . Compared to pure amorphous drugs, ASDs have a higher physical and chemical stability due to reduced molecular mobility, which also will increase the glass transition temperature of the system [6] .
To reduce the "pill burden" and increase compliance, many of the currently marketed ASDs are formulated with a relatively high drug loading. However, even though it is physically stabilized in a polymer, the drug in an ASD can also be thermodynamically unstable if the drug load exceeds its equilibrium solubility in the polymer at storage temperature [10, 7] . This situation will eventually lead to two potential outcomes: either the drug will separate to form local amorphous drugrich clusters (amorphous phase separation) and/or the drug will nucleate and crystallize. Both of these events will significantly change the physicochemical properties of the formulation [11, 2] . Consequently, overloading the drug in the ASD will not only affect the overall physical https://doi.org/10.1016/j.ejpb.2018.07.005 Received 31 May 2018; Received in revised form 2 July 2018; Accepted 3 July 2018 stability, but may also lead to variable performance and ultimately lower bioavailability over time and hence, constitutes a major regulatory, efficiency and safety issue [12] .
Therefore, the aim of this study was to evaluate the influence of amorphous phase separation and crystallization on the in vitro and in vivo performance of an ASD of celecoxib (CCX) in polyvinylpyrrolidone (PVP). The amorphous phase-separated and crystallized ASDs were prepared by mixing a homogenous ASD (glass solution) of CCX in PVP with pure amorphous or micronized crystalline CCX at 20, 40, 60 or 100% of the total drug load (25:75 w/w CCX), respectively. The performance of these formulations was then evaluated by non-sink in vitro dissolution testing in fasted-state simulated intestinal fluid (FaSSIF) and in vivo in rats and compared to that of crystalline CCX, amorphous CCX and pure ASD.
Materials and methods

Materials
Celecoxib (CCX, M w = 381.37 g/mol), sodium chloride, sodium dihydrogen phosphate monohydrate, sodium hydroxide, hydrogen chloride, 0.1% trifluoracetic acid and acetonitrile were purchased from VWR (Leuven, Belgium). Kollidon® 30 (PVP, M w = 44,000-54,000 g/ mol) was kindly supplied by BASF (Ludwigshafen, Germany) and SIF™ Powder instant biorelevant medium was purchased from Biorelevant.com Ltd (London, United Kingdom).
Sample preparation
The pure ASD and amorphous CCX were prepared by melt quenching. CCX and PVP were weighed (25% w/w CCX) and mixed thoroughly using a mortar and pestle. The physical mixture was then spread evenly on aluminum foil and placed in an electrical furnace at 169°C for 5 min. The mixture was removed from the furnace, allowed to cool to room temperature and pulverized using a mortar and pestle. For the ASD this procedure was repeated to ensure homogeneity. The resulting powders were sieved through a 0.2 mm sieve and stored in airtight amber containers until use.
For the preparation of the amorphous phase-separated and crystallized ASDs, ASDs of different CCX concentration (5, 10, 15 and 25% w/ w) were prepared using the aforementioned melt quenching method and mixed thoroughly with micronized crystalline CCX (to better mimic the particle size of crystallized drug in the ASD) or freshly prepared amorphous CCX using a mortar and pestle to yield 20, 40, 60 or 100% amorphous phase-separated or crystallized ASD. In all the ASDs, the total CCX concentration was fixed at 25% w/w and named after their relative fraction of amorphous phase-separated or crystallized CCX. For example, 40% amorphous phase-separated ASD refers to a system where 40% of the total dose of CCX has amorphous phase-separated and 60% is still dispersed/dissolved in the polymer. The successful formation of amorphous phase-separated ASDs (as evident from two separate glass transitions and no melting event) and crystallized ASDs (as evident from a single glass transition and a melting event) was confirmed using differential scanning calorimetry and X-ray powder diffraction (see Supplementary Material).
Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ejpb.2018.07.005.
Preparation of dissolution media
For the non-sink dissolution studies, FaSSIF (version 1) was used as the dissolution medium and was prepared following the instructions provided by Biorelevant.com. To prepare 1 L of FaSSIF, 1 L of pH 6.5 20 mM phosphate buffer was first prepared by dissolving 0.42 g sodium hydroxide pellets, 3.95 g sodium dihydrogen phosphate monohydrate and 6.19 g of sodium chloride in 900 mL of purified filtered Milli-Q water. The pH was then adjusted to 6.50 ± 0.05 with 0.1 N sodium hydroxide or hydrochloric acid and finally, the volume was increased to 1000 mL with Milli-Q water. A total of 2.12 g of the SIF powder was weighed and added to approximately 500 mL of the phosphate buffer and when completely dissolved, the volume was increased to 1000 mL with the buffer and kept on a magnetic stirrer for at least 2 h until use. The FaSSIF was used within 24 h of preparation as recommended by the manufacturer.
In vitro dissolution
The non-sink dissolution studies were performed on a VanKel VK 7000 USP II apparatus equipped with a VK 750D/K heating device from VanKel Technology Group (Cary, NC, USA). A total of 300 mL of freshly prepared FaSSIF was added to each dissolution chamber and allowed to equilibrate at 37°C. The remaining FaSSIF was stored in an oven at 37.5°C. The dissolution studies were initialized by pre-suspending the formulation at a dose corresponding to 400 mg CCX in 100 mL FaSSIF in a beaker by rigorous stirring. This suspension was then immediately added to the dissolution chamber, and an additional 100 mL FaSSIF was used to rinse the beaker of any remaining drug formulation and added to the dissolution chamber to yield a total of 500 mL FaSSIF (and 800 µg/mL CCX). Samples of 2 mL were withdrawn from each chamber at predetermined time points (1, 5, 10, 15, 20, 30, 45, 60, 90 , 120, 180, 240, 360 and 1440 min) with a syringe and filtered into a 4 mL black cap vial with a Spartan Whatman 0.22 µm syringe filter from GE Health Care (Chicago, IL, USA). From this vial, 1 mL of the filtrate was immediately diluted with 1 mL of methanol to prevent precipitation from supersaturated samples and assayed for CCX content by UPLC (see below).
In vivo study
The procedure for the in vivo study was approved by the local Animal Welfare Committee. All animal procedures were carried out in compliance with EC Directive 2010/63/ EU, NIH Guide for the Care and Use of Laboratory Animals, and with the Belgian laws regulating experiments on animals.
Male Sprague-Dawley rats (∼300 g) were purchased from Charles River Laboratories (Sulzfeld, Germany). To avoid food effects, all rats were fasted 16-20 h prior to the study and until 8 h after dosing. Immediately before oral dosing, the formulations were suspended in 30 mL FaSSIF at a concentration corresponding to 10 mg/mL CCX using a magnetic stirrer and dosed to each rat individually at 10 mL/kg by oral gavage (n = 3-5). A total of 42 rats were randomly assigned to one of the following groups, each consisting of 3-5 animals: (i) amorphous CCX (n = 5), (ii) pure ASD (25:75 w/w) of CCX-PVP (n = 5), (iii) 20% crystallized ASD (n = 5), (iv) 40% crystallized ASD (n = 5), (v) 60% crystallized ASD (n = 5), (vi) 100% crystallized ASD (n = 5), (vii), 20% amorphous phase-separated ASD (n = 3), (viii) 40% amorphous phaseseparated ASD (n = 3), (ix) 60% amorphous phase-separated ASD (n = 3), (x) 100% amorphous phase-separated ASD (n = 3). Blood samples of 100 μL were collected at 0.5, 1, 2, 3, 4, 6, 8 and 24 h after administration by individual lateral tail vein puncture and transferred to ethylenediaminetetraacetic acid (EDTA)-coated tubes to prevent coagulation. The blood samples were then centrifuged for 10 min at 3600 ×g and the plasma was subsequently transferred to labeled plastic tubes and stored at −80°C until analysis. After collection of the last sample, the animals were euthanized.
Quantitative analysis
The method of analysis for the in vitro dissolution samples was developed on an Acquity ultra performance liquid chromatograph (UPLC) equipped with an Acquity UPLC BEH C18 column, both from Waters Corp. (Milford, MA, USA), using a mobile phase consisting of triflouroacetic acid (TFA) 0.1% in water and acetonitrile in a 70:30 v/v ratio, respectively. The diluted samples were mixed on a VVR whirlmixer and added to a 96 well plate in which 100 µg/mL CCX in methanol standards were added as reference. A volume of 1-3 μL was eluted at a flow rate of 0.6 mL/min with a column oven temperature of 55°C, and the effluent was detected at a wavelength of 251 nm after approximately 1.7 min. A standard curve was prepared by analyzing CCX in methanol in concentrations between 1 μg/mL and 250 μg/mL, resulting in a standard curve with a linear correlation of R 2 = 0.999.
The concentration of CCX in plasma was determined using UPLC chromatography with MS/MS detection. A quantity of 10 μL plasma was mixed with 10 μL blank plasma, 20 μL DMSO and 200 μL of acetonitrile. The samples were centrifuged at 6000 ×g for 20 min at 5°C. Analysis of the plasma samples was performed by UPLC connected to a tandem mass spectrometer (MS/MS) using a Waters Acquity Ultra Performance Liquid Chromatograph system (Waters Corp., Milford, MA) equipped with a binary solvent delivery system (pump), a sample manager module with autosampler, and a column compartment/heater. A switch valve connected the UPLC to the mass spectrometer. The MS/ MS detection was performed using a SCIEX API 4000 MS/MS system with a Turbo Ion Spray® (ESI) as an interface (Applied Biosystems, Carlsbad, CA), operating in the positive ion electrospray mode. Operational settings: CCX was detected at a precursor product ion mass to charge ratio (m/z) of 316. Collision gas (CAD) 6.0, temperature (TEM) 550°C, IS -4500 V, Entrance potential (EP) -10.0 V and collision energy (CE) -32.0 V. For the UPLC analysis, chromatographic separation was performed on a Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7 μm) from Waters Corp. (Milford, MA, USA). The mobile phases contained 0.1% formic acid in water (A) and methanol (B). The total run time was 1.7 min and a gradient system was used. The gradient conditions were 80.0% A and 20.0% B from initial time to 1 min, 90% A and 10% B from 1 to 1.15 min and finally 80.0% A and 20.0% B from 1.15 to 1.7 min. The flow rate was 0.80 mL/min. The column temperature was maintained at 40°C, and the injection volume was 1.0 μL. A lower limit of quantification (LLOQ) and an upper limit of quantification (ULOQ) of 10 and 40,000 ng/mL, respectively, were obtained.
Data analysis
Results from the in vitro study are expressed as mean ± SD and data from the in vivo study are expressed as mean ± SEM. Statistical analysis of the in vivo data was performed in SigmaPlot 13.0 from Systat Software Inc. (Chicago, IL, USA). The primary pharmacokinetic parameters: area under the plasma concentration-time profile (AUC 0-24h ), maximum plasma concentration (C max ) and time to reach C max (t max ) were obtained by non-compartmental analysis of the plasma data. A one-way analysis of variance (ANOVA) followed by a pairwise multiple comparison Student-Newman-Keuls test was performed on untransformed data in order to identify significant differences of C max and AUC 0-24h and differences in t max were analyzed using a Mann-Whitney rank sum test for the paired samples. A statistical p value < 0.05 was considered significant.
Results and discussion
Crystallization
The in vitro dissolution profiles and in vivo plasma concentrationtime profiles following administration of the different crystallized ASDs are shown in Figs. 1 and 2 , respectively. The corresponding (pharmacokinetic) parameters, maximum (plasma) concentration (C max ) of CCX, time to reach C max (t max ), and area under the dissolution (AUC 0-4h ) and plasma concentration-time curves (AUC 0-24h ) are provided in Tables 1  and 2 , respectively. The area under the dissolution curve (in vitro AUC 0-4h ) is calculated from 0 to 4 h as the gastrointestinal transit time of rats is 3-4 h and a previous study showed that this concentration-time profile is predictive of in vivo bioavailability of CCX ASDs [8] .
As can be seen in Fig. 1 and Table 1 , the in vitro t max increased and the AUC 0-4h and C max decreased (almost linearly) with an increasing fraction of crystallized drug, respectively, which was somewhat expected given that both the dissolution rate and (apparent) solubility of 
Table 1
In vitro parameters after non-sink dissolution testing of the crystallized ASDs at a dose of 400 mg (values are mean ± SD, n = 3). 
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the amorphous form of a drug is higher than that of its crystalline counterpart [9] . This suggests that the performance of an ASD is significantly affected by crystallization of the drug in the ASD. By comparing the in vitro C max for the crystalline CCX and the 100% crystallized ASD it is clear that PVP has some solubilizing properties, i.e. it increases the equilibrium solubility of crystalline CCX in the solution (from 54.9 to 60.8 µg/mL) most likely due to drug-polymer interactions [2] . Therefore, based on the in vitro dissolution study it is expected that the mere presence of PVP in the 100% crystallized ASD will improve the performance of the system compared to pure crystalline CCX. Nevertheless, this improved performance pales in comparison with the effect from formulating the drug as an ASD, which more than quadruples the in vitro AUC 0-4h . This substantial increase in performance (AUC) of the pure ASD was also reflected in the in vivo study as shown in Fig. 2 and Table 2 . In accordance with the observations in vitro, the t max for the pure and crystallized ASDs were significantly lower than for crystalline CCX, which was probably a result of the lower dissolution rate of the crystalline CCX compared to amorphous CCX. Similarly, both the in vivo C max and AUC 0-24h decreased with increasing fraction of crystallization with the pure ASD and the 20% and 40% crystallized ASDs being significantly higher than for the 100% crystallized ASDs (and crystalline CCX). Compared to 100% crystallized ASD and crystalline CCX, the in vivo AUC 0-24h for the pure ASD was approximately 2-fold and 3-fold higher, respectively, which indicates that crystallization has a significant impact on the in vivo performance of an ASD. In order to illustrate this influence, the in vivo AUC 0-24h is plotted as a function of crystallized CCX fraction in Fig. 3 .
As can be seen, there is a good linear correlation between the in vivo AUC 0-24h and fraction of crystallized CCX, which suggests that crystallization of a drug in an ASD during storage has significant impact on the in vivo performance or bioavailability of the drug. Nevertheless, the difference between the in vivo AUC 0-24h and C max for the pure ASD and the 20% and 40% crystallized ASDs was not statistically significant. This indicates that, despite the good correlation between the in vivo AUC 0-24h and % of crystallization of CCX, these systems could be bioequivalent.
A test product can be considered bioequivalent with a reference product if the 90% confidence interval for AUC and C max of the test product both fall within 80-125% of those of the reference product [18] . The 90% confidence interval for the test product is given by X ± Z·s/√n, where X is the mean, Z is the standard normal variable (=1.645 for 90% confidence interval), s is the standard variation and n is the number of samples. Hence, in order to be considered bioequivalent with the pure ASD, the 90% confidence intervals for in vivo AUC 0-24h and C max for the crystallized ASDs should fall within 235.6-368.1 µg·h/mL and 20.6-32.2 µg/mL, respectively. For the 20% and 40% crystallized ASDs the 90% confidence intervals for in vivo AUC 0-24h and C max was 205.1-336.5 and 242.7-272.3 µg·h/mL, and 21.8-28.9 and 20.3-24.1 µg/mL, respectively. This means that the 20% crystallized ASD is bioequivalent to the pure ASD with regards to in vivo C max and the 40% crystallized ASD was bioequivalent with regards to in vivo AUC 0-24h . However, as none of the crystallized ASDs fall within the limits of the pure ASD for both pharmacokinetic parameters, they cannot be considered bioequivalent.
The lack of bioequivalence between the pure ASD and the 20% crystallized ASD was probably a result of the high standard deviation on the AUC 0-24h due to the relatively low number of animals (n = 5). Accordingly, bioequivalence between the 20% crystallized ASD and the pure ASD could probably be established if the number of animals is increased to n = 10-12. In combination with the lack of statistical significance between the AUC 0-24h and C max for the pure ASD and the 20% and 40% crystallized ASDs, this could indicate that a small fraction (up to 20% w/w) of crystallized drug in an ASD only have limited or no impact on the in vivo performance and bioavailability. In fact, considering that the crystals formed within an ASD during storage were most likely much smaller than the micronized drug particles used in this study (nm vs. µm scale), the effect of crystallization on the performance of the ASD was expected to be even less pronounced than demonstrated above. Nevertheless, this claim would have to be investigated in further detail in future studies in humans.
Amorphous phase separation
The in vitro dissolution profiles and in vivo plasma concentrationtime profiles following administration of the different amorphous phase-separated ASDs are shown in Figs. 4 and 5 , respectively. The corresponding (pharmacokinetic) parameters, maximum (plasma) concentration (C max ) of CCX, time to reach C max (t max ), and area under the dissolution (AUC 0-4h ) and plasma concentration-time curves (AUC 0-24h ) are provided in Tables 3 and 4 , respectively.
As can be seen in Fig. 4 and Table 3 , the in vitro t max generally increased with increasing fraction of amorphous phase-separated CCX (except for the 60% phase-separated ASD). However, the t max for the pure amorphous CCX was shorter than for the pure ASD (13.3 vs. 45.0 min). This difference could be due to the dissolution rate of the amorphous CCX being higher than the dissolution rate of PVP as drug release from an ASD is driven by the dissolution of the polymer [11] . However, by comparing the dissolution profile of the amorphous CCX with the 100% amorphous phase-separated ASD it is clear that PVP, besides having solubilizing properties (as shown in Table 1 ), also inhibited the crystallization of the drug from the supersaturated solution by delaying the onset of crystallization as implied from the increase in Table 2 Pharmacokinetic parameters of the various crystallized ASDs administered to rats at a dose of 100 mg/kg (values are mean ± SEM, n = 5). t max . This increase in dissolution rate followed by inhibition/delay of crystallization of drug from the supersaturated solution is a well-known property of many polymeric ASDs (such as CCX-PVP) and based on the appearance of the non-sink dissolution profile it is referred to as the "spring and parachute" effect [2, 5] . Furthermore, the in vitro AUC 0-4h and C max decreased with increasing fraction of amorphous phase separation, however, not to the same extent as for the crystallized ASDs ( Fig. 1 and Table 1 ). In fact, the difference between the in vitro AUC 0-4h for the pure ASD and the 20% and 40% amorphous phase-separated ASDs was only around 10%, which suggests that based on the in vitro dissolution study, amorphous phase separation may not have a significant influence on the performance of an ASD. These findings were in accordance with a study by Chen et al. [3] , who demonstrated that amorphous phase separation of a slow crystallizing drug in an ASD only had minimal impact on the in vitro dissolution performance. Indeed, at first glance, amorphous phase separation did not seem to have significant influence on the in vivo performance (in vivo AUC 0-4h and C max ) of the ASD as shown in Fig. 5 and Table 4 . In contrast to the in vivo study of the crystallized ASDs, there was no significant difference between t max of the pure and amorphous phase-separated ASDs and amorphous CCX. However, in accordance with the observations in vitro (despite a lack of statistical significance), the in vivo t max of for amorphous CCX was lower than that for all the crystallized ASDs, which was probably a result of the absence of the precipitation inhibitor PVP. In addition, both the in vivo C max and AUC 0-24h decreased with increasing fraction of crystallization with both pharmacokinetic parameters for the pure ASD and the 20% and 40% amorphous phase-separated ASDs being significantly higher than 100% phase-separated ASD and amorphous CCX. Nevertheless, compared to 100% phase-separated ASD and amorphous CCX, the in vivo AUC 0-24h for the pure ASD was only 1.3-fold and 1.9-fold higher, respectively, which suggest that the influence of phase separation of a drug in an ASD, may not be as significant when compared to the effect of crystallization. In order to illustrate the influence of amorphous phase separation on the in vivo performance of an ASD, the in vivo AUC 0-24h is plotted as a function of amorphous phaseseparated CCX fraction in Fig. 6 .
As can be seen, in contrast to the data presented in Fig. 3 , the in vivo AUC 0-24h did not appear to decrease linearly with increasing fraction of amorphous phase-separated CCX. Rather it seemed that the curve was S-shaped, which indicated that lower fractions of amorphous phase separation (≤40% w/w) did not affect the performance of an ASD. In fact, the lack of statistical significant differences between the AUC 0-24h and C max for the pure ASD and the amorphous phase-separated ASDs suggests that these systems were bioequivalent.
As mentioned above, in order to be bioequivalent with the pure ASD, the 90% confidence intervals should fall within 235.6-368.1 µg h/ mL for AUC 0-24h and 20.6-32.2 µg/mL for C max . For the 20% and 40% amorphous phase-separated ASDs, the 90% confidence intervals for AUC 0-24h is 235.8-352.1 and 256.-315.5 µg h/mL, and the 90% confidence intervals for C max is 21.1-27.4 and 21.7-27.4 µg/mL, respectively. This means that the 20% and 40% amorphous phase-separated ASDs can indeed be considered bioequivalent with the pure ASD. In combination with the lack of statistical significance between the AUC 0-24h and C max for the pure ASD and these systems, this strongly indicated that even a substantial fraction (up to 40% w/w) of amorphous phase separation of the drug in an ASD during storage may not significantly impede the performance or bioavailability of the formulation. 
Table 3
In vitro parameters after non-sink dissolution testing of the amorphous phase-separated ASDs at a dose of 400 mg (values are mean ± SD, n = 3). 
Conclusions
The present study addresses the issues related to the efficiency and safety of crystallized or amorphous phase-separated ASDs as a result of the change in physicochemical properties of the system. The results demonstrated that both the in vitro and in vivo performance of an ASD was indeed influenced by crystallization or phase-separation of the drug. As expected, crystallization of CCX in the ASDs generally had a negative influence on performance compared to the pure ASD. However, the difference between the in vivo AUC of the pure ASD and the 20% and 40% crystallized ASDs was not statistically significant, which could indicate that a small fraction of crystallization of the drug in an ASD (e.g. below 20% w/w) would only have limited or no impact on in vivo performance/bioavailability. In comparison, amorphous phase separation of CCX in the ASDs did not negatively influence the in vitro and in vivo AUC to the same degree as crystallization. In fact, even though a slight decrease of in vivo AUC with increasing fraction of amorphous phase separation was observed, the 20% and 40% amorphous phase-separated ASDs were bioequivalent with the pure ASD. Even though only one drug-polymer systems was investigated, the findings of this study indicate that the general reservations towards the impact of amorphous phase separation and crystallization of the drug in an ASD on its bioavailability may be exaggerated. Fig. 6 . Relationship between the fraction of amorphous phase-separated CCX (% w/w) in the ASDs and in vivo AUC 0-24h . ± SEM (n = 3-5). Table 4 Pharmacokinetic parameters of the various amorphous phase-separated ASDs administered to rats at a dose of 100 mg/kg (values are mean ± SEM, n = 3-5). Significantly different at p < 0.05: a vs. amorphous CCX; b vs. 100% amorphous phase-separated ASD.
